1Baselga J, Averbuch S: ZD1839(′Iressa′) as an anticancer agent. Drug 2000,60(Supple 1):30.
2Hidalgo M, Siu L,Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001,19:3267.
3Baselga J, Yano S, Giaccone G, et al: Initial result from a Phase Ⅱ trial of ZD1839(′Iressa′) as second- and third-line monotherapy for patients with advanced non-small- cell lung cancer(IDEAL 1)[abstract]. Clin Cancer Res 2001,7:3780S.
4Manegnld C: ECCO 11 welcomes EGFR-trageted anticancer agents. Signal 2002,3:13.
5Alan E Wakeling: Epidermal growth factor receptor tyrosine kinase inhibitors: Current Opinion in Pharmacology 2002,2:382.
6Mecclelland RA, Barrow D, Madden T-A, et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast can cer cells after long- term culture in the presence of the pure antiestrogen ICI 182,780(Faslodex). Endocrinology 2001,142: 2776.
7Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab(Herceptin)[J]. Sernin Oncol, 1999,26(Supple 12):S60.
8Al Hazaa A, Birchall Ma, Bowen ID. ZD1839(Iressa), an EGFR-TKI,and cisplatin have an additive effect on procarcinoma cells in vitro. Clin Cancer Res,2000,6(11):4542S.
9Kris MG, Herbst R, Rischin D, et al. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839(Iressa),a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor(EGFR)[J]. Lung cancer,2000,29(Supplel):72(abstract).
10Sirotnak F, Zakowski M, Miller V, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839(Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res,2000,6(12);4885.
